Randomized trial compares oxytocin, oxytocin+misoprostol, and carbetocin for C-section blood loss prevention

Postpartum hemorrhage (PPH) remains a critical obstetric emergency and a leading cause of maternal morbidity and mortality, accounting for approximately 25% of all maternal deaths worldwide. Uterotonic agents are crucial for its prevention during the third stage of labor and after cesarean section. While oxytocin is the most widely used agent, its efficacy can be variable, and alternatives or adjuncts are continually explored. Carbetocin, a longer-acting oxytocin analog, and misoprostol, a prostaglandin E1 analog, are potential candidates to improve uterine contractility and reduce bleeding, addressing a significant gap in current PPH prevention strategies.

This study randomized patients undergoing cesarean section into three groups to compare peroperative and postoperative blood loss. The first group received oxytocin alone. The second group received oxytocin in combination with intrauterine misoprostol. The third group received carbetocin. The primary endpoint for this comparison was the mean blood loss during the cesarean section, with secondary aims likely including postoperative blood loss. The study design is a randomized controlled trial, aiming to provide robust comparative data on these uterotonic regimens for PPH prevention.

The abstract for this study details the experimental design and objectives but does not present any specific findings or numerical results regarding the comparative efficacy of the interventions. The primary outcome sought was a reduction in mean blood loss during cesarean section, with secondary outcomes likely including postoperative blood loss and potentially adverse events. A successful outcome would demonstrate a statistically significant difference in blood loss between the groups, ideally identifying an intervention superior to oxytocin alone. Such findings would typically include mean blood loss values for each group, along with p-values or confidence intervals indicating the significance of any observed differences. Without these results, the study's impact on clinical practice remains to be determined, pending full publication of the data. The study's design, however, is robust for comparing these common uterotonic strategies.